Citius Pharmaceuticals, Inc. (CTXR)

Citius Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Net Income	-37.43	-39.14	-32.54	-33.64	-23.05
Depreciation & Amortization	0.21	0.21	0.19	0.18	0.16
Stock-Based Compensation	10.86	12.12	6.72	4.28	1.52
Other Operating Activities	-1.25	0.29	0.58	0.58	-0.17
Change in Inventory	-12.65	-2.13	-	-	-
Change in Accounts Payable	8.77	2	1.76	-0.11	-0.58
Change in Other Net Operating Assets	4.94	-1.55	-5.77	0.35	-2.14
Operating Cash Flow	-26.55	-28.2	-29.06	-28.36	-24.25
Capital Expenditures	-	-	-	-	-0.01
Sale (Purchase) of Intangibles	-5.75	-5	-	-	-40
Investing Cash Flow	-5.75	-5	-	-	-40.01
Short-Term Debt Issued	1.3	-	-	-	-
Total Debt Issued	1.3	-	-	-	-
Short-Term Debt Repaid	-0.3	-	-	-	-0.17
Total Debt Repaid	-0.3	-	-	-	-0.17
Net Debt Issued (Repaid)	1	-	-	-	-0.17
Issuance of Common Stock	32.3	13.8	15.03	-	127.71
Other Financing Activities	-	-3.83	-1.2	-	-7.07
Financing Cash Flow	33.3	9.97	13.83	-	120.47
Net Cash Flow	1	-23.23	-15.23	-28.36	56.21
Free Cash Flow	-26.55	-28.2	-29.06	-28.36	-24.26
Free Cash Flow Per Share	-2.40	-4.19	-4.80	-4.85	-5.58
Cash Interest Paid	0.19	-	-	-	0.04
Levered Free Cash Flow	-23.38	8.02	-19.85	-15.94	-55.61
Unlevered Free Cash Flow	-23.21	8.02	-19.85	-15.94	-55.61
Change in Working Capital	1.05	-1.69	-4.01	0.24	-2.72

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q